Tweet
Most Bio-Pharma have no profits because of all the research , but CORT is different!
Cort http://finviz.com/quote.ashx?t=CORT&ty=c&ta=1&p=d 2nd Chart: http://schrts.co/mwrkhX
Corcept Therapeutics Inc. (NasdaqGS:CORT) is a $1.08 billion biotech company which targets a disease called Cushing’s Syndrome, an ailment where tumors in the body produce excess cortisol, or compounds which go on to produce excess cortisol. An estimated 20,000 Americans suffer from this serious and sometimes fatal illness, and only half have received surgical treatment. For the other 10,000, there’s Korlym®. Korlym is a once-daily pill to block the activity of cortisol and high blood sugar, a key effect of Cushing’s. Already approved by the FDA, it puts CORT in rare company as a small biotech with an FDA-APPROVED drug that can help tens of thousands of patients around the globe. It also puts CORT on a bullet train to profitability.
From 2013 to 2015, the company’s top line has grown 385.52% from $10.38 million to $50.29 million. Over the same time frame, its net income has improved from -$46 million in 2013 to -$6.4 million in 2015. By the end of 2016 and 2017, the Street expects the company will earn $0.05 per share and $0.26 per share, respectively, based on the average estimate of analysts. That amounts to an expected 420% earnings increase from 2016 to 2017.
Quarterly revenue jumped 63.8% year-over-year in CORT’s earnings report released earlier this month, marking a surge that other small biotechs without an FDAapproved treatment on the market can only dream of. Cash on hand is also extremely healthy at more than $47 million, giving management an important buffer as it nurtures the rest of its pipeline, which includes clinical trials for treatments targeting breast cancer, oncologic diseases, and even psychiatric conditions. So as you can see Cort's growth potential is "HUGE"
Folks read this document about some financial aspects of CORT. One pundit on the internet says that you could probably QUADRUPLE your money over time. http://ih.advfn.com/p.php?pid=nmona&...64&symbol=CORT
Cort http://finviz.com/quote.ashx?t=CORT&ty=c&ta=1&p=d 2nd Chart: http://schrts.co/mwrkhX
Corcept Therapeutics Inc. (NasdaqGS:CORT) is a $1.08 billion biotech company which targets a disease called Cushing’s Syndrome, an ailment where tumors in the body produce excess cortisol, or compounds which go on to produce excess cortisol. An estimated 20,000 Americans suffer from this serious and sometimes fatal illness, and only half have received surgical treatment. For the other 10,000, there’s Korlym®. Korlym is a once-daily pill to block the activity of cortisol and high blood sugar, a key effect of Cushing’s. Already approved by the FDA, it puts CORT in rare company as a small biotech with an FDA-APPROVED drug that can help tens of thousands of patients around the globe. It also puts CORT on a bullet train to profitability.
From 2013 to 2015, the company’s top line has grown 385.52% from $10.38 million to $50.29 million. Over the same time frame, its net income has improved from -$46 million in 2013 to -$6.4 million in 2015. By the end of 2016 and 2017, the Street expects the company will earn $0.05 per share and $0.26 per share, respectively, based on the average estimate of analysts. That amounts to an expected 420% earnings increase from 2016 to 2017.
Quarterly revenue jumped 63.8% year-over-year in CORT’s earnings report released earlier this month, marking a surge that other small biotechs without an FDAapproved treatment on the market can only dream of. Cash on hand is also extremely healthy at more than $47 million, giving management an important buffer as it nurtures the rest of its pipeline, which includes clinical trials for treatments targeting breast cancer, oncologic diseases, and even psychiatric conditions. So as you can see Cort's growth potential is "HUGE"
Folks read this document about some financial aspects of CORT. One pundit on the internet says that you could probably QUADRUPLE your money over time. http://ih.advfn.com/p.php?pid=nmona&...64&symbol=CORT
Comment